Latest Breaking News On - Global head of oncology development at novartis - Page 1 : comparemela.com

Novartis' innovative drug shows significant positive outcomes in Phase III trial for patients with gastrointestinal cancers - Pharma News

Novartis' innovative drug shows significant positive outcomes in Phase III trial for patients with gastrointestinal cancers - Pharma News
financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.

Toronto
Ontario
Canada
United-states
Sunnybrook
Alberta
American
Jeff-legos
Simron-singh
University-of-toronto
Odette-cancer-centre
American-society-of-clinical-oncology

Novartis Pharma AG: Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors

Novartis Pharma AG: Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Switzerland
China
Toronto
Ontario
Canada
Sunnybrook
Alberta
Ivrea
Piemonte
Italy
United-states
Haiyan

Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors

In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median PFS to 22.8 months vs. 8.5 months with high-dose octreotide LAR in patients with newly diagnosed grade 2.

United-states
Haiyan
Yunnan
China
Italy
Sasayama
Hyogo
Japan
Canada
Spain
Zhejiang
Zaragoza

Novartis Lutathera® Phase III trial results

Novartis Lutathera® significantly reduced the risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors.In the.

Jeff-legos
Novartis-lutathera
Global-head-of-oncology-development-at-novartis
Global-head
Oncology-development
Markets

Novartis Pharma AG: Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions

Novartis Pharma AG: Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

San-antonio
Texas
United-states
Lugano
Ticino
Switzerland
Paris
France-general
France
Chicago
Illinois
Spain